Home> Products> Inhibitors> NMS-1286937-CAS 1034616-18-6
price inquiry for CAS:1034616-18-6, Product:NMS-1286937
For research use only. We do not sell to patients.

NMS-1286937 CAS: 1034616-18-6

Category: Inhibitors
Product Name: NMS-1286937
Cat No: I000207
CAS No: 1034616-18-6
Synonyms: None
Molecular Formula: C24H27F3N8O3
Molecular Weight: 532.52
InChI: None
InChIKey: None
Solubility: DMSO: ≥ 21 mg/mL
Target: PLK
IC50: 2 nM [1]
Storage: Store at -20°C
CAS 1034616-18-6,NMS-1286937
  • Description

NMS-1286937(NMS-P937) is an orally bioavailable, small-molecule Polo-like kinase 1 (PLK1) inhibitor(IC50=2 nM) with potential antineoplastic activity; no inhibition on PLK2 and PLK3.
IC50 value: 2 nM [1]
Target: PLK1
in vitro: NMS-P937 potently causes a mitotic cell-cycle arrest followed by apoptosis in cancer cell lines and inhibits xenograft tumor growth with clear PLK1-related mechanism of action at well-tolerated doses in mice after oral administration. In addition, NMS-P937 shows potential for combination in clinical settings with approved cytotoxic drugs, causing tumor regression in HT29 human colon adenocarcinoma xenografts upon combination with irinotecan and prolonged survival of animals in a disseminated model of acute myelogenous leukemia in combination with cytarabine [2].
in vivo: We therefore tested our PLK1 inhibitor NMS-P937 in this model either in the engraftment or in the established disease settings. Both schedules showed good efficacy compared to standard therapies, with a significant increase in median survival time (MST) expecially in the established disease setting (MST=28, 36, 62 days for vehicle, cytarabine and NMS-P937, respectively). Importantly, we could also demonstrate that NMS-P937 induced specific biomarker modulation in extramedullary tissues. This new in vivo model of CD56(+) AML that recapitulates the human tumour lends support for the therapeutic use of PLK1 inhibitors in AML [3].

  • Spec

Appearance:Solid powder
Purity: > 98%

  • References

[1]. Beria I, et al. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett. 2011 May 15;21(10):2969-74.
[2]. Valsasina B, et al. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther. 2012 Apr;11(4):1006-16.
[3]. Casolaro A, et al. The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. PLoS One. 2013;8(3):e58424.

price inquiry for CAS:1034616-18-6, Product:NMS-1286937
Advanced Biomart